Five-year HELIOS-B data presented at AHA 2026 showed that patients who began vutrisiran (AMVUTTRA) at trial outset rather than after a delay had a 48% lower risk of all-cause mortality and recurrent cardiovascular events in the monotherapy population, with a 41% reduction in the overall cohort. Cardiac biomarkers remained stable, quality-of-life scores improved, and a post hoc exercise analysis showed preserved peak oxygen uptake. In transthyretin amyloid cardiomyopathy, the interval before treatment begins appears to shape outcomes as much as the treatment itself.
Key Points
- Continuous vutrisiran cut mortality and recurrent cardiovascular events 48%
- Delayed treatment start produced persistently worse five-year outcomes
- NT-proBNP, troponin I and peak oxygen uptake remained stable
Longevity Analysis
Amyloid deposition in cardiac tissue is a progressive, largely irreversible structural burden, and silencing the hepatic production of the misfolded precursor protein works by removing the source of interference rather than compensating downstream. The separation between early and delayed treatment arms over sixty months quantifies the cost of diagnostic lag in a condition frequently mistaken for ordinary heart failure with preserved ejection fraction. Preserved peak oxygen uptake alongside stable biomarkers indicates that the heart's pumping capacity and the oxygen delivery it supports were held, not merely slowed in decline.
Original published by LT Wire.